Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Study sponsor: Replimune, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-09Estimated
Enrollment · participants231Actual
Source updated2025-01-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.